AZN

Coronavirus treatment hopes boost European stocks at open

Credit: REUTERS/STAFF

European stocks bounced from a two-week low on Monday as signs of progress in developing a COVID-19 treatment offset fears about a resurgence in virus cases across the continent that could risk stifling an economic recovery.

For a live blog on European stocks, type LIVE/ in an Eikon news window

Aug 24 (Reuters) - European stocks bounced from a two-week low on Monday as signs of progress in developing a COVID-19 treatment offset fears about a resurgence in virus cases across the continent that could risk stifling an economic recovery.

The pan-European STOXX 600 index .STOXX rose 1.3% by 0713 GMT, mirroring gains for Asian markets after the U.S. health regulator said on Sunday it authorized the use of blood plasma from patients who have recovered from COVID-19 as a treatment.

Technology .SX8P, mining .SXPP and chemical .SX4P companies led the surge in early European trading, gaining more than 1.5%.

AstraZeneca Plc AZN.L was up 2.1% after the Financial Times reported the Trump administration was considering fast-tracking an experimental COVID-19 vaccine being developed by the company.

The gains come after a lacklustre week for European equities, which were pressured by data pointing to a stalling business recovery in the euro zone amid a surge in coronavirus cases.

British telecoms company BT Group BT.L jumped 6.1% to the top of STOXX 600 after a media report that its board was preparing to defend it against takeover approaches from rivals and buyout firms.

(Reporting by Sruthi Shankar in Bengaluru; Editing by Anil D'Silva)

((sruthi.shankar@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2787;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More